ASH 2018

ASH 2018 - Peter Hoogerbrugge, PhD, Tisagenlecleucel in Acute Lymphoblastic Leukemia

Peter Hoogerbrugge, PhD Pediatric Oncologist, Prinses Maxima Centrum, Utrecht

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

...Lees meer

0120HEM1291233

Hematologie

ALL

Afdrukken

ASH 2018 Stephan A. Grupp, MD, PhD, Tisagenlecleucel in Acute Lymphoblastic Leukemia

Stephan A. Grupp, MD, PhD Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia,

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

...Lees meer

0120HEM1291233

Hematologie

ALL

Andere categorieën

Afdrukken

ASH 2018 - James Baumgardner, PhD, CAR-T Health Outcomes and Competitive Cost-Effectiveness

James Baumgardner, PhD Precision Health Economics, Los Angeles, CA

CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments

...Lees meer

0120HEM1291233

Hematologie

ALL

Andere categorieën

Afdrukken

ASH 2018 - Jason R. Gotlib, MD, MS, The New Tool KIT in Advanced Systemic Mastocytosis

Jason R. Gotlib, MD, MS Stanford Cancer Institute, Stanford, CA

The New Tool KIT in Advanced Systemic Mastocytosis

https://ash.confex.com/ash/2018/webprogram/Paper109399.html

0120HEM1291431

Hematalks

Afdrukken

ASH 2018 - Francesco Passamonti, MD, Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly

Francesco Passamonti, MD Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy

Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study

...Lees meer

0120HEM1291431

Hematologie

ASH 2018

Andere categorieën

Hematalks

Afdrukken

ASH 2018 - Susanne Isfort, Thromboembolic Events worsen QoL

Susanne Isfort Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in...Lees meer

0120HEM1291431

Hematologie

ASH 2018

Andere categorieën

MPN

Afdrukken

ASH 2018 - Ruben Mesa, PhD, MPN and MF study results

Ruben Mesa, PhDRuben Mesa PhD UT Health San Antonio Cancer Center, San Antonio

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders...Lees meer

0120HEM1291431

Hematologie

ASH 2018

Andere categorieën

Afdrukken

ASH 2018 - Natasha Szuber, MD, MPN studies

Natasha Szuber, MD Division of Hematology, Mayo Clinic, Montreal, QC, Canada

Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

0120HEM1291431

Afdrukken

ASH 2018 - Prof dr. Arjan van de Loosdrecht

Prof dr. Arjan van de Loosdrecht, internist-hematoloog, Amsterdam UMC, Amsterdam

Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic...Lees meer

0120HEM1291431

Hematologie

ASH 2018

Hematalks

Afdrukken

ASH 2018 Prof. dr. Peter Hoogerbrugge

Prof. dr. Peter Hoogerbrugge, kinderarts-oncoloog, Prinses Maxima Centrum, Utrecht

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia...Lees meer

0120HEM1291431

Hematologie

ASH 2018

Hematalks

Afdrukken

×

Popular Search

Recent News

ASH 2018

ASH 2018 - Peter Hoogerbrugge, PhD, Tisagenlecleucel in Acute Lymphoblastic Leukemia

ASH 2018 Stephan A. Grupp, MD, PhD, Tisagenlecleucel in Acute Lymphoblastic Leukemia

ASH 2018 - James Baumgardner, PhD, CAR-T Health Outcomes and Competitive Cost-Effectiveness

ASH 2018 - Jason R. Gotlib, MD, MS, The New Tool KIT in Advanced Systemic Mastocytosis

ASH 2018 - Francesco Passamonti, MD, Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly

ASH 2018 - Susanne Isfort, Thromboembolic Events worsen QoL

ASH 2018 - Ruben Mesa, PhD, MPN and MF study results

ASH 2018 - Natasha Szuber, MD, MPN studies

ASH 2018 - Prof dr. Arjan van de Loosdrecht

ASH 2018 Prof. dr. Peter Hoogerbrugge

Ask Speakers

Ask Speakers

Medical Information Request